Analysis of Platelet Parameters and Activation Markers in Hematologic Metastases of Lung Cancer
Lung cancer (LC) remains one of the most prevalent and deadly malignancies worldwide. Despite advancements in understanding its etiology and progression, the mechanisms underlying its metastasis, particularly through hematologic pathways, are not fully elucidated. Recent studies have highlighted the role of platelets (PLTs) in facilitating tumor cell aggregation, immune evasion, and metastasis. This study delves into the relationship between platelet parameters, activation markers, and the progression of lung cancer, with a focus on hematologic metastases.
Introduction
Lung cancer is a complex disease characterized by uncontrolled cell growth in lung tissues. Metastasis, the spread of cancer cells to distant organs, is a critical factor in the prognosis and treatment of LC. Hematologic metastasis, where cancer cells disseminate through the bloodstream, is a common route for LC progression. Platelets, traditionally known for their role in hemostasis and thrombosis, have recently been implicated in cancer progression. Tumor cells interact with platelets to evade immune detection, adhere to vascular endothelial cells, and promote metastasis. This interaction leads to a hypercoagulable state and enhanced platelet function, which in turn supports tumor growth and invasion.
The study aims to explore the impact of lung cancer on circulating platelets, focusing on platelet counts, activation markers, and their correlation with disease progression. By analyzing these parameters, the research seeks to provide insights into the role of platelets in LC metastasis and identify potential therapeutic targets.
Materials and Methods
The study was conducted at the 96th Hospital of the People’s Liberation Army of China, involving 40 patients diagnosed with lung cancer (LC group) and 50 healthy individuals (control group). The LC group comprised 28 men and 12 women, with a mean age of 58.08 ± 10.22 years. The control group included 32 men and 18 women, with a mean age of 58.52 ± 11.93 years. All participants provided written informed consent, and the study adhered to ethical regulations approved by the hospital’s Ethics Committee.
Blood samples were collected from fasting participants in the morning. Participants had not received hemostasis or anticoagulant medication for at least two weeks prior to sampling. Platelet counts were determined using an automatic blood analyzer, and thromboelastograms were generated using a thromboelastograph. Additionally, 30 non-small cell lung cancer (NSCLC) patients and 20 control individuals were selected for the determination of CD62P positivity, a marker of platelet activation.
Platelet-rich plasma was isolated from peripheral blood samples through centrifugation. The plasma was then incubated with specific antibodies (CD61-FITC + IgG1-PE for the negative control and CD61-FITC + CD62P-PE for the study group) and analyzed using flow cytometry. The CD62P positivity rate was calculated as the percentage of CD61+CD62P+ cells relative to total CD61+ cells.
Results
The study revealed significant differences in platelet parameters between the LC group and the control group. The LC group exhibited lower values for reaction time (R), K time (K), and platelet distribution width (PDW). In contrast, values for angle, maximum amplitude (MA), coagulation composite index (CI), platelet count, mean platelet volume (MPV), and fibrinogen (FIB) were higher in the LC group.
Platelet counts in the LC group averaged 250.60 ± 57.09 × 10^9/L, significantly higher than the control group’s 192.35 ± 43.37 × 10^9/L. The CD62P positivity rate was also markedly higher in the LC group (50.42 ± 15.42%) compared to the control group (27.31 ± 18.16%).
Patients were further stratified based on the 2017 clinical TNM staging system into early-stage (I/II) and late-stage (III/IV) groups. The MA values were significantly higher in the late-stage group, indicating increased platelet aggregation in advanced disease. Platelet counts and CD62P positivity rates increased progressively with disease stage. For instance, stage I patients had platelet counts of 193.44 ± 42.03 × 10^9/L, while stage IV patients had counts of 293.75 ± 34.79 × 10^9/L. Similarly, CD62P positivity rates rose from 42.34 ± 14.31% in stage I to 63.45 ± 15.02% in stage IV.
Discussion
The findings underscore the pivotal role of platelets in lung cancer progression and metastasis. Elevated platelet counts and enhanced platelet activation, as indicated by CD62P positivity, are associated with advanced disease stages. These changes reflect a hypercoagulable state, which facilitates tumor cell survival, immune evasion, and metastasis.
Platelets interact with tumor cells through various mechanisms, including adhesion, aggregation, and the release of growth factors. These interactions promote tumor cell survival in the bloodstream, adhesion to endothelial cells, and extravasation into distant tissues. The study’s results align with previous research showing that high platelet numbers and fibrinogen levels are common in NSCLC patients with local or distant metastasis.
The thromboelastography (TEG) analysis revealed increased MA values in LC patients, indicating enhanced platelet aggregation. This finding suggests that tumor-induced changes in coagulation and fibrinolysis contribute to the hypercoagulable state observed in cancer patients. The progressive increase in platelet counts and CD62P positivity with disease stage highlights the potential of these parameters as biomarkers for disease progression and prognosis.
Structural and functional changes in platelets play a crucial role in their interaction with tumor cells. Platelet activation leads to the release of microparticles and growth factors that support tumor growth and angiogenesis. The overexpression of membrane glycoproteins, such as CD62P, further enhances platelet adhesion and aggregation, promoting thrombosis and metastasis.
The study’s findings have significant clinical implications. Early-stage patients exhibited lower platelet counts and CD62P positivity rates, suggesting that platelet function inhibition could be a viable therapeutic strategy in early disease. In contrast, late-stage patients with high platelet counts and activation markers may benefit from therapies targeting platelet function to reduce metastasis and improve outcomes.
Conclusion
This study provides comprehensive insights into the role of platelets in lung cancer progression and hematologic metastasis. Elevated platelet counts and activation markers are associated with advanced disease stages, highlighting their potential as biomarkers for disease monitoring and therapeutic targets. The findings underscore the importance of understanding platelet-tumor interactions in developing effective strategies to combat lung cancer metastasis.
Future research should focus on elucidating the molecular mechanisms underlying platelet activation in cancer and exploring therapeutic interventions targeting platelet function. By addressing these aspects, it may be possible to develop novel treatments that disrupt the platelet-mediated pathways supporting tumor growth and metastasis, ultimately improving patient outcomes.
doi.org/10.1097/CM9.0000000000000138
Was this helpful?
0 / 0